Avidian Wealth Enterprises LLC Takes Position in Enovis Co. (NYSE:ENOV)

Avidian Wealth Enterprises LLC bought a new position in shares of Enovis Co. (NYSE:ENOV) during the fourth quarter, Holdings Channel.com reports. The fund bought 5,978 shares of the company’s stock, valued at approximately $262,000.

Several other hedge funds have also recently added to or reduced their stakes in the company. Diamond Hill Capital Management Inc. increased its holdings in shares of Enovis by 7.8% in the 3rd quarter. Diamond Hill Capital Management Inc. now owns 3,004,694 shares of the company’s stock valued at $129,352,000 after acquiring an additional 218,660 shares during the last quarter. DAVENPORT & Co LLC boosted its holdings in shares of Enovis by 6.0% in the 4th quarter. DAVENPORT & Co LLC now owns 2,782,341 shares of the company’s stock valued at $121,181,000 after buying an additional 157,216 shares in the last quarter. Royce & Associates LP grew its position in shares of Enovis by 16.8% in the 3rd quarter. Royce & Associates LP now owns 2,403,685 shares of the company’s stock valued at $103,479,000 after buying an additional 346,317 shares during the last quarter. State Street Corp grew its position in shares of Enovis by 4.3% in the 3rd quarter. State Street Corp now owns 1,647,220 shares of the company’s stock valued at $70,913,000 after buying an additional 68,190 shares during the last quarter. Finally, River Road Asset Management LLC purchased a new stake in Enovis in the third quarter valued at $51,341,000. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Trading Up 0.4 %

NYSE ENOV opened at $43.89 on Friday. The firm’s fifty day moving average is $45.37 and its two-hundred day moving average is $44.40. Enovis Co. has a one year low of $38.27 and a one year high of $65.03. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.12 and a current ratio of 2.27. The firm has a market cap of $2.50 billion, a PE ratio of -20.04 and a beta of 1.94.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC reaffirmed a “buy” rating and set a $65.00 price objective on shares of Enovis in a report on Thursday, November 7th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $64.83.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.